Abstract 25P
Background
Epithelial ovarian cancer (EOC) is a disease found mainly in advanced stages and difficult to treat. The study of the expression and methylation of miRNA genes can become the basis for the development of potential new diagnostic and prognostic markers of EOC, as well as the basis for the development of targeted anticancer therapy.
Methods
80 paired samples of EOC (ovarian serous adenocracinoma) were obtained from the National Medical Research Center of Oncology named after N.N. Blokhin. MicroRNA expression was assessed by TaqMan-qPCR with kits from Applied Biosystems, USA. Analysis of methylation of promoter CpG islands of microRNA genes was carried out using bisulfite conversion followed by methyl-specific PCR.
Results
The methylation frequency in the tumor was higher than in paired norm for 10 microRNA genes (MIR-124-1, -124-2, -124-3, -125B-1, -127, -129-2, -132, -137, -193A and -339; p ≤ 5×10-4). ROC analysis showed that a combination of 4 microRNA genes (MIR-124-2, -127, -129-2, -137) can be proposed as a panel of EOC detection markers with sensitivity (Sn) 80%, specificity (Sp) 82 %, AUC=0.86. The combination of miRNA genes (MIR-193A, -129-2, -137) was characterized by Sn=90%, Sp=75% and AUC=0.90. For 5 out of 12 microRNAs studied, a high frequency of reduced expression was observed: miR-125b-5p - in 59% of tumor samples compairing to paired norms, miR-129-5p - in 55%, miR-132-3p - in 55%, miR-137 - in 52% , and miR-193a-5p in 66% (p ≤ 0.05). The correlation of changes in the expression of 12 microRNAs (miR-124-3p, -125b-5p, -127-5p, 129-5p, -132-3p, -137, -148a-3p, -191-5p, -193a-5p, -203a, -339-3p and -375) and changes in methylation of the genes encoding them rs=0.67-0.97 (according to Spearman), p ≤ 10-4.
Conclusions
The role of methylation in the regulation of the expression of 12 microRNAs and the association of the methylation status of 10 microRNA genes with EOC metastasis were revealed. 5 microRNAs downregulated by hypermethylation may find use as potential targets for EOC therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The state task FGFU-2022-0007 of the Ministry of Science and Higher Education of the Russian Federation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
53P - Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
Presenter: Francesco Bertoni
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC
Presenter: Tina Jost
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells
Presenter: Martin Hohenegger
Session: Cocktail & Poster Display session
Resources:
Abstract
56P - Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma
Presenter: Kelsey Gauthier
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Deciphering the role of E2F transcription factor-1 in glutamine metabolism
Presenter: Katharina Huber
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low-expressing breast cancer cells and organoid mode
Presenter: Maryam Arshad
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - The influence of the ABCB1, ABCG2 and OATP1 transporters and the CYP3A enzyme on the bioavailability and tissue distribution of TPX-0131
Presenter: Jamie Rijmers
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
Presenter: Emilien Ezine
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma
Presenter: Jiyoon Jung
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
Presenter: ANGSHUMAN SARKAR
Session: Cocktail & Poster Display session
Resources:
Abstract